Chammas & Marcheteau

Press release

Paris, December 2, 2025

Chammas & Marcheteau advises Turenne Santé on Ventuno Biotech's €3M seed financing (Biotechnology/Healthcare)

Chammas & Marcheteau advised Turenne Santé in connection with Ventuno Biotech's €3 million seed financing, which includes a €2 million equity investment led by Octalfa alongside Relyens Innovation Santé advised by Turenne Santé, with the participation of business angels.

Founded in early 2025, Ventuno Biotech is a French biotechnology company developing innovative immunotherapies aimed at stimulating antitumor immune responses to treat cancers that are resistant to current therapies.

This financing will enable Ventuno Biotech to strengthen its discovery and translational research programs in immuno-oncology and advance its portfolio of first-in-class immunotherapies toward their next development milestones.

The Chammas & Marcheteau team consisted of Jérôme Chapron (partner) and Nessrine Berrad (associate) on corporate aspects, Aude Spinasse (partner) and Constance Parini (associate) on intellectual property aspects, and Coline Bied-Charreton (partner) and Emmanuel Corbel (associate) on employment law aspects.

About Chammas & Marcheteau

Chammas & Marcheteau is a Paris-based independent law firm that advises companies, investment funds and entrepreneurs on their transactions and development strategies in France and abroad. With more than 60 specialists in business law, including 16 partners, the Firm offers its clients expertise in Private Equity, Mergers & Acquisitions, Funds and Financial Services, Corporate, Restructuring and Turnaround, Tax, Intellectual Property and Information Technology, Employment Law, Real Estate and Business Litigation.